Latest & greatest articles for anticoagulation

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on anticoagulation or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on anticoagulation and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for anticoagulation

1. Oral anticoagulants for primary prevention, treatment and secondary prevention of venous thromboembolic disease, and for prevention of stroke in atrial fibrillation: systematic review, network meta-analysis and cost-effectiveness analysis

Oral anticoagulants for primary prevention, treatment and secondary prevention of venous thromboembolic disease, and for prevention of stroke in atrial fibrillation: systematic review, network meta-analysis and cost-effectiveness analysis Oral anticoagulants for primary prevention, treatment and secondary prevention of venous thromboembolic disease, and for prevention of stroke in atrial fibrillation: systematic review, network meta-analysis and cost-effectiveness analysis Journals Library (...) A Davies 1 , Jose A López-López 1 , George N Okoli 1 , Howard HZ Thom 1 , Deborah M Caldwell 1 , Sofia Dias 1 , Diane Eaton 4 , Julian PT Higgins 1 , Will Hollingworth 1 , Chris Salisbury 1 , Jelena Savović 1 , Reecha Sofat 5, 6 , Annya Stephens-Boal 7 , Nicky J Welton 1 , Aroon D Hingorani 5, 6 1 School of Social and Community Medicine, University of Bristol, Bristol, UK 2 University College London Hospitals, NHS, London, UK 3 Royal National Orthopaedic Hospital, NHS, London, UK 4 AntiCoagulation

2017 NIHR HTA programme

2. Meta-analysis of efficacy and safety of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus warfarin in patients with atrial fibrillation

Meta-analysis of efficacy and safety of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus warfarin in patients with atrial fibrillation Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2012 DARE.

3. Management of Patients on Non?Vitamin K Antagonist Oral Anticoagulants in the Acute Care and Periprocedural Setting: A Scientific Statement From the American Heart Association

Management of Patients on Non?Vitamin K Antagonist Oral Anticoagulants in the Acute Care and Periprocedural Setting: A Scientific Statement From the American Heart Association e604 March 7, 2017 Circulation. 2017;135:e604–e633. DOI: 10.1161/CIR.0000000000000477 ABSTRACT: Non–vitamin K oral anticoagulants (NOACs) are now widely used as alternatives to warfarin for stroke prevention in atrial fibrillation and management of venous thromboembolism. In clinical practice, there is still widespread (...) , and prescriptions for long-term anticoagulation will climb. Anticoagulated patients are vulnerable to spontane- ous, traumatic and perioperative bleeding. Warfarin is a vitamin K antagonist (VKA) that has been used for decades to prevent and treat arterial and venous thromboem- bolism (VTE). More recently, 4 non–vitamin K antagonist oral anticoagulants (NOACs) have been approved in the United States as alternatives to warfarin for prevention of stroke resulting from nonvalvular AF (NVAF), and prevention

Full Text available with Trip Pro

2017 American Heart Association

4. Interventional Spine and Pain Procedures in Patients on Antiplatelet and Anticoagulant Medications

Interventional Spine and Pain Procedures in Patients on Antiplatelet and Anticoagulant Medications Interventional Spine and Pain Procedures in Patients on Anti... : Regional Anesthesia and Pain Medicine You may be trying to access this site from a secured browser on the server. Please enable scripts and reload this page. Login No user account? Lippincott Journals Subscribers , use your username or email along with your password to log in. Remember me on this computer Register for a free account (...) Procite Reference Manager Save my selection doi: 10.1097/AAP.0000000000000700 CHRONIC AND INTERVENTIONAL PAIN: SPECIAL ARTICLE Free The American Society of Regional Anesthesia and Pain Medicine (ASRA) 2012 survey of meeting attendees showed that existing ASRA anticoagulation guidelines for regional anesthesia were insufficient for their needs. Those surveyed agreed that procedure-specific and patient-specific factors required separate guidelines for pain and spine procedures. In response, a guidelines

2018 American Society of Regional Anesthesia and Pain Medicine

5. Use of Non-Vitamin K Antagonist Oral Anticoagulants (NOAC) in Non-Valvular Atrial Fibrillation

Use of Non-Vitamin K Antagonist Oral Anticoagulants (NOAC) in Non-Valvular Atrial Fibrillation Use of Non-Vitamin K Antagonist Oral Anticoagulants (NOAC) in Non-Valvular Atrial Fibrillation - Province of British Columbia theme_3_collection theme_3_frontend theme_3_collection theme_3_frontend Birth, Adoption, Death, Marriage & Divorce theme_1_collection theme_1_frontend theme_1_collection theme_1_frontend British Columbians & Our Governments theme_data_collection data_frontend (...) Safety & Emergency Services theme_10_collection theme_10_frontend theme_10_collection theme_10_frontend Sports, Recreation, Arts & Culture theme_8_collection theme_8_frontend theme_8_collection theme_8_frontend Taxes & Tax Credits theme_14_collection theme_14_frontend theme_14_collection theme_14_frontend Tourism & Immigration Search default_collection default_frontend Section Navigation Use of Non-Vitamin K Antagonist Oral Anticoagulants (NOAC) in Non-Valvular Atrial Fibrillation Effective Date

2015 Clinical Practice Guidelines and Protocols in British Columbia

6. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials

Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials Ruff CT, Giugliano RP, Braunwald E (...) , Hoffman EB, Deenadayalu N, Ezekowitz MD, Camm AJ, Weitz JI, Lewis BS, Parkhomenko A, Yamashita T, Antman EM CRD summary This review concluded that new oral anticoagulants offered significant reductions in stroke, intracranial haemorrhage, and mortality, compared with warfarin, with a similar risk of major bleeding and an increased risk of gastrointestinal bleeding. Despite shortcomings in the reporting, these conclusions are likely to be reliable. Authors' objectives To assess the efficacy and safety

2014 DARE.

7. Oral anticoagulation with warfarin - 4th edition

Oral anticoagulation with warfarin - 4th edition Guidelines on oral anticoagulation with warfarin – fourth edition - Keeling - 2011 - British Journal of Haematology - Wiley Online Library By continuing to browse this site, you agree to its use of cookies as described in our . Search within Search term Search term The full text of this article hosted at iucr.org is unavailable due to technical difficulties. guideline Free Access Guidelines on oral anticoagulation with warfarin – fourth edition (...) can be found at . The objective of this guideline is to provide healthcare professionals with clear guidance on the indications for and management of patients on warfarin. This guideline replaces the previous BCSH guidelines on oral anticoagulants ( ; ). 1. Indications for warfarin and recommended target international normalized ratio (INR) This guideline refers to target INRs rather than target ranges, although the target range is generally taken to be within 0·5 of the target, i.e. a target INR

Full Text available with Trip Pro

2011 British Committee for Standards in Haematology

8. Anticoagulants in non-valvular atrial fibrillation

Anticoagulants in non-valvular atrial fibrillation Anticoagulants in non-valvular atrial fibrillation Anticoagulants in non-valvular atrial fibrillation Van Brabandt H, San Miguel L, Fairon N, Vaes B, Henrard S, Boshnakova A, Cook R, Davies R, Karnad A, Lovell A, Dubois C Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Van Brabandt H, San (...) Miguel L, Fairon N, Vaes B, Henrard S, Boshnakova A, Cook R, Davies R, Karnad A, Lovell A, Dubois C. Anticoagulants in non-valvular atrial fibrillation. Brussels: Belgian Health Care Knowledge Centre (KCE). KCE Reports. 2017 Authors' conclusions • International practice guidelines recommend prescribing anticoagulants to patients with non-valvular atrial fibrillation and a CHA2DS2-VASc score ≥ 2 (for men) and score ≥ 3 (for women). For a CHA2DS2-VASc score = 0 they are best not prescribed. In patients

2017 Health Technology Assessment (HTA) Database.

9. Antiplatelet and anticoagulant agents for secondary prevention of stroke and other thromboembolic events in people with antiphospholipid syndrome. (PubMed)

Antiplatelet and anticoagulant agents for secondary prevention of stroke and other thromboembolic events in people with antiphospholipid syndrome. Antiphospholipid syndrome (APS) is a systemic autoimmune disease characterized by arterial or venous thrombosis (or both) and/or pregnancy morbidity in association with the presence of antiphospholipid antibodies. The prevalence is estimated at 40 to 50 cases per 100,000 people. The most common sites of thrombosis are cerebral arteries and deep veins (...) of the lower limbs. People with a definite APS diagnosis have an increased lifetime risk of recurrent thrombotic events.To assess the effects of antiplatelet or anticoagulant agents, or both, for the secondary prevention of recurrent thrombosis, particularly ischemic stroke, in people with antiphospholipid syndrome.We searched the Cochrane Stroke Group Trials Register (February 2017), CENTRAL (last search February 2017), MEDLINE (from 1948 to February 2017), Embase (from 1980 to February 2017), and several

Full Text available with Trip Pro

2017 Cochrane

10. Direct acting oral anticoagulants likely to be better than warfarin for people taking them for atrial fibrillation

Direct acting oral anticoagulants likely to be better than warfarin for people taking them for atrial fibrillation Direct acting oral anticoagulants likely to be better than warfarin for people taking them for atrial fibrillation Discover Portal Discover Portal Direct acting oral anticoagulants likely to be better than warfarin for people taking them for atrial fibrillation Published on 6 February 2018 doi: In people with atrial fibrillation needing anticoagulant treatment, deaths were fewer (...) in those who had direct acting oral anticoagulants compared with warfarin. The picture is less clear for the risk of stroke and complications such as bleeding in the brain or gut. Apixaban had the best efficacy and safety profile and was cost-effective compared with warfarin. This study pooled the data in all trials reporting efficacy, safety and cost of anticoagulant prevention of stroke events in people with atrial fibrillation. Researchers used a technique called network meta-analysis to compare

2018 NIHR Dissemination Centre

11. Interventional Spine and Pain Procedures in Patients on Antiplatelet and Anticoagulant Medications

Interventional Spine and Pain Procedures in Patients on Antiplatelet and Anticoagulant Medications Interventional Spine and Pain Procedures in Patients on Anti... : Regional Anesthesia and Pain Medicine You may be trying to access this site from a secured browser on the server. Please enable scripts and reload this page. Login No user account? Lippincott Journals Subscribers , use your username or email along with your password to log in. Remember me on this computer Register for a free account (...) and anticoagulant medications were insufficient for their needs. Those surveyed agreed that procedure-specific and patient-specific factors necessitated separate guidelines for pain and spine procedures. In response, ASRA formed a guidelines committee. After preliminary review of published complication reports and studies, committee members stratified interventional spine and pain procedures according to potential bleeding risk as low-, intermediate-, and high-risk procedures. The ASRA guidelines were deemed

2015 American Society of Regional Anesthesia and Pain Medicine

12. Direct oral anticoagulants versus warfarin for preventing stroke and systemic embolic events among atrial fibrillation patients with chronic kidney disease. (PubMed)

Direct oral anticoagulants versus warfarin for preventing stroke and systemic embolic events among atrial fibrillation patients with chronic kidney disease. Chronic kidney disease (CKD) is an independent risk factor for atrial fibrillation (AF), which is more prevalent among CKD patients than the general population. AF causes stroke or systemic embolism, leading to increased mortality. The conventional antithrombotic prophylaxis agent warfarin is often prescribed for the prevention of stroke (...) , but risk of bleeding necessitates regular therapeutic monitoring. Recently developed direct oral anticoagulants (DOAC) are expected to be useful as alternatives to warfarin.To assess the efficacy and safety of DOAC including apixaban, dabigatran, edoxaban, and rivaroxaban versus warfarin among AF patients with CKD.We searched the Cochrane Kidney and Transplant Specialised Register (up to 1 August 2017) through contact with the Information Specialist using search terms relevant to this review. Studies

Full Text available with Trip Pro

2017 Cochrane

13. Direct acting oral anticoagulants likely to be better than warfarin for people taking them for atrial fibrillation

Direct acting oral anticoagulants likely to be better than warfarin for people taking them for atrial fibrillation Direct acting oral anticoagulants likely to be better than warfarin for people taking them for atrial fibrillation Discover Portal Discover Portal Direct acting oral anticoagulants likely to be better than warfarin for people taking them for atrial fibrillation Published on 6 February 2018 doi: In people with atrial fibrillation needing anticoagulant treatment, deaths were fewer (...) in those who had direct acting oral anticoagulants compared with warfarin. The picture is less clear for the risk of stroke and complications such as bleeding in the brain or gut. Apixaban had the best efficacy and safety profile and was cost-effective compared with warfarin. This study pooled the data in all trials reporting efficacy, safety and cost of anticoagulant prevention of stroke events in people with atrial fibrillation. Researchers used a technique called network meta-analysis to compare

2019 NIHR Dissemination Centre

14. Anticoagulants in non-valvular atrial fibrillation

Anticoagulants in non-valvular atrial fibrillation 2017 www.kce.fgov.be KCE REPORT 279 ANTICOAGULANTS IN NON-VALVULAR ATRIAL FIBRILLATION 2017 www.kce.fgov.be KCE REPORT 279 HEALTH TECHNOLOGY ASSESSMENT ANTICOAGULANTS IN NON-VALVULAR ATRIAL FIBRILLATION HANS VAN BRABANDT, LORENA SAN MIGUEL, NICOLAS FAIRON, BERT VAES, SEVERINE HENRARD, ANELIA BOSHNAKOVA, ROB COOK, ROB DAVIES, ADITI KARNAD, ALAN LOVELL, CECILE DUBOIS COLOPHON Title: Anticoagulants in non-valvular atrial fibrillation Authors: Hans (...) responsibility of the KCE. Publication date: 9 januari 2017 Domain: Health Technology Assessment (HTA) MeSH: atrial fibrillation; anticoagulants; secondary prevention; Belgium; cost-benefit analysis; Practice Patterns, Physicians'; Practice Guidelines as Topic NLM Classification: QV 193 Language: English Format: Adobe® PDF™ (A4) Legal depot: D/2016/10.273/101 ISSN: 2466-6459 Copyright: KCE reports are published under a “by/nc/nd” Creative Commons Licence http://kce.fgov.be/content/about-copyrights-for-kce

2017 Belgian Health Care Knowledge Centre

15. Anticoagulant therapy for deep vein thrombosis (DVT) in pregnancy. (PubMed)

Anticoagulant therapy for deep vein thrombosis (DVT) in pregnancy. Thromboembolic complications are much higher in pregnancy due to procoagulant changes. Heparin does not cross the placenta and the use of unfractionated heparin (UFH) is the current established practice in prophylaxis and treatment for thromboembolism in pregnancy.To compare the effectiveness of anticoagulant therapies for the treatment of deep vein thrombosis in pregnancy. The anticoagulant drugs included are UFH, low molecular (...) did not identify any eligible studies for inclusion in the review.We identified three potential studies; after assessing eligibility, we excluded all three as they did not meet the prespecified inclusion criteria. One study compared LMWH and UFH in pregnant women with previous thromboembolic events and, for most of these women, anticoagulants were used as thromboprophylaxis. There were only three women who had a thromboembolic event during the current pregnancy and it was unclear whether

Full Text available with Trip Pro

2010 Cochrane

16. Comparative effectiveness of warfarin and new oral anticoagulants for the management of atrial fibrillation and venous thromboembolism: a systematic review

Comparative effectiveness of warfarin and new oral anticoagulants for the management of atrial fibrillation and venous thromboembolism: a systematic review Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2012 DARE.

17. Antiplatelet and anticoagulant drugs for ST-elevation myocardial infarction (STEMI)

Antiplatelet and anticoagulant drugs for ST-elevation myocardial infarction (STEMI)

2017 DynaMed Plus

18. Antiplatelet versus anticoagulation treatment for patients with heart failure in sinus rhythm. (PubMed)

Antiplatelet versus anticoagulation treatment for patients with heart failure in sinus rhythm. Morbidity in patients with chronic heart failure is high, and this predisposes them to thrombotic complications, including stroke and thromboembolism, which in turn contribute to high mortality. Oral anticoagulants (e.g. warfarin) and antiplatelet agents (e.g. aspirin) are the principle oral antithrombotic agents. Many heart failure patients with sinus rhythm take aspirin because coronary artery (...) disease is the leading cause of heart failure. Oral anticoagulants have become a standard in the management of heart failure with atrial fibrillation. However, a question remains regarding the appropriateness of oral anticoagulants in heart failure with sinus rhythm. This update of a review previously published in 2012 aims to address this question.To assess the effects of oral anticoagulant therapy versus antiplatelet agents for all-cause mortality, non-fatal cardiovascular events and risk of major

Full Text available with Trip Pro

2016 Cochrane

19. Direct oral anticoagulants or warfarin for A fib?

Direct oral anticoagulants or warfarin for A fib? Direct oral anticoagulants or warfarin for A fib? Toggle navigation Shared more. Cited more. Safe forever. Toggle navigation View Item JavaScript is disabled for your browser. Some features of this site may not work without it. Search MOspace This Collection Browse Statistics Direct oral anticoagulants or warfarin for A fib? View/ Open Date 2017-08 Format Metadata Abstract A recent study evaluated the effectiveness of 3 direct oral (...) anticoagulants and warfarin in patients with atrial fibrillation. So which agents came out on top? PRACTICE CHANGER: Use direct oral anticoagulants instead of warfarin in patients with atrial fibrillation because they are just as effective at preventing ischemic stroke and systemic emboli as warfarin, and because apixaban and dabigatran have lower bleeding rates. Stength of recommendation: B: Based on a single, prospective, cohort study. URI Part of Citation Journal of Family Practice, 66(8) 2017: 518-520

2018 PURLS

20. Anticoagulant treatment for subsegmental pulmonary embolism. (PubMed)

Anticoagulant treatment for subsegmental pulmonary embolism. Acute pulmonary embolism (PE) is a common cause of death, accounting for 50,000 to 200,000 deaths annually. It is the third most common cause of mortality among the cardiovascular diseases, after coronary artery disease and stroke.The advent of multi-detector computed tomographic pulmonary angiography (CTPA) has allowed better assessment of PE regarding visualisation of the peripheral pulmonary arteries, increasing its rate (...) imaging performed for other reasons (for example routine CT for cancer staging in oncologic patients).Traditionally, all PEs are anticoagulated in a similar manner independent of the location, number and size of the thrombi. It has been suggested that many patients with SSPE may be treated without benefit, increasing adverse events by possible unnecessary use of anticoagulants.Patients with isolated SSPE or incidental PE may have a more benign clinical presentation compared with those with proximal

2016 Cochrane